Data investigation
Another Molecule You Cannot Buy
A dual agonist reported 14.7% weight loss in thirteen weeks. The drug is approved nowhere, and a thirteen-week figure sits on the steepest part of a curve that flattens.
A phase 2 trial of VK2735, another dual GIP/GLP-1 agonist, reported 14.7% weight loss in thirteen weeks.[1] That is a faster rate than anything on the market has published, and it is about to be quoted without the second half of the sentence. The drug is not approved anywhere, and a thirteen-week result cannot be stretched into a year, because the curve flattens.
What the trial reported
VENTURE enrolled adults carrying excess weight who also had at least one condition tied to it, excluded anyone with diabetes, and assigned them weekly injections of VK2735 at one of several strengths or a placebo, for 13 weeks.
| Group | Weight change | Percent |
|---|---|---|
| VK2735 2.5 mg | −9.2 kg | −9.1% |
| VK2735 15 mg | −14.6 kg | −14.7% |
| Placebo | −1.8 kg | −1.7% |
Across the active arms, 130 of 140 people (93%) shed 5% or more. On placebo, 4 of 34 did. Adverse events were gastrointestinal, as expected, and became less frequent once the dose stopped climbing.
Why you cannot annualize this
The fair comparison is with where the established drugs stood at their thirteenth week, not with a 68- or 72-week result, and those earlier figures are not reported alongside this one. A short trial can look extraordinary purely by being measured during the steep part of the curve.
The trial itself is a dose-ranging phase 2 doing what a dose-ranging phase 2 should. The caution is about the sentence that will circulate.
The endpoint the abstract does not report
The trial’s stated secondary endpoints include the proportion of participants losing at least 5% and the proportion losing at least 10%. The published abstract reports the first (93% against 12%) but not the second.
The 10% threshold is the more informative of the two, because 5% is cleared by most people on any drug in this class and does not discriminate between them. We do not know what that figure was, we are not going to estimate it, and its absence from a summary that reports its companion deserves a reader’s attention.
And it is not something you can be prescribed
VK2735 has moved on to phase 3. Two 78-week trials, VANQUISH 1 in about 4,500 people without diabetes and VANQUISH 2 in about 1,100 with it, started in June 2025 and have finished enrolling; ClinicalTrials.gov estimates primary completion in July 2027.[2][3] Until those report, the drug has no approval in any country, no label, no approved manufacturer, and no route to a pharmacy. In practice that means the same thing it meant for retatrutide: a promising early result raises demand that the legitimate supply chain cannot meet, and unlabeled vials appear online to fill the gap.
Until VANQUISH 1 and 2 report, VK2735 has no approval in any country, no label and no route to a pharmacy.
The material used in this trial was manufactured to clinical-trial standard, at a verified concentration, with a known impurity profile. A powder sold under the same name has none of those properties verified, because there is no approved product to verify it against. The same reasoning, at greater length, is in retatrutide’s phase 3 and the gray market.
Frequently Asked Questions
References
- 1.Bays HE, Toth P, Alkhouri N, et al. Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study Obesity. 2026. PMID: 41508550.
- 2.U.S. National Library of Medicine VK2735 for Weight Management Phase 3 (VANQUISH 1), NCT07104500 ClinicalTrials.gov, accessed October 17, 2026. 2026. https://clinicaltrials.gov/study/NCT07104500
- 3.U.S. National Library of Medicine VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2), NCT07104383 ClinicalTrials.gov, accessed October 17, 2026. 2026. https://clinicaltrials.gov/study/NCT07104383
Compare the sellers
Related research
Retatrutide's Phase 3, and the Gray Market
A triple-receptor agonist cut HbA1c 1.94 points and weight 15.3% in a phase 3 trial. It is approved nowhere, and eight sellers in our register are already shipping something by that name.
8 min read
A Composite Is Only Its Components
A reanalysis found tirzepatide getting far more patients to three or more treatment targets. The comparator was semaglutide at 1 mg, and the gap was carried by two of the four targets.
7 min read
Who Was Actually in the Trials
Every result comes with an unstated question: does it apply to you? A review of 246 trials and 139,566 participants shows who was studied, and the mismatch has a consistent shape.
7 min read
The Mental Health Score That Did Not Move
In the head-to-head trial, physical quality-of-life scores improved clearly over 72 weeks. The Mental Component Summary did not significantly improve in either arm, a result the paper's own conclusion omits.
6 min read
Comparing Trials That Never Met
We refused a cross-trial comparison in an earlier article. This article runs the methodologically proper version of it, and explains why it appears to contradict a head-to-head trial without actually doing so.
7 min read
When Pooling Studies Hides the Answer
A meta-analysis of 323,439 patients found no significant cardiovascular advantage for tirzepatide. The more important number sits beside it: the studies being pooled disagree with each other almost completely.
7 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
WellMedRx
Comparing compounded and brand GLP-1 plans with a published state list
From $49/mo
Get started →Collective
Flat any-dose pricing, if you can absorb a $199 annual membership on top
From $59/mo + membership
Get started →Embody
A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
From $79/mo
Get started →